Interleukin Genetics, Inc. to Present at the 2010 Rodman & Renshaw Annual Global Investment Conference

Published on Wednesday, 08 September 2010 16:42 Written by TradersHuddle Staff

WALTHAM, Mass., Sept. 8 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Rodman & Renshaw Annual Global Investment Conference, taking place at the New York Palace Hotel in New York City, Sept. 12-15, 2010.  The corporate presentation is scheduled for Tuesday, Sept. 14 at 11:15 a.m. in the Spellman Salon on the 5th Floor.  

In addition, Mr. Bender is scheduled to participate in a panel discussion titled "Navigating the Changing Regulatory Landscape of Laboratory Developed Tests" on Sept. 14 at 8 a.m. in the Spellman Salon on the 5th Floor.

Company management will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Investment Conference.  For those who would like to schedule an appointment with Interleukin Genetics' management, please contact your Rodman & Renshaw representative. 

The presentation will be webcast live at www.ilgenetics.com, where it will also be archived for 90 days.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand.  The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA).  For more information please visit www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.